Phase Diagrams Map the Properties of Antiviral Agents Directed against Hepatitis B Virus Core Assembly

Lichun Li,a Srinivas Reddy Chirapu,b M. G. Finn,b Adam Zlotnicka

Department of Molecular and Cellular Biochemistry, Indiana University, Bloomington, Indiana, USA; Department of Chemistry and Biochemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California, USA

Assembly effectors are small molecules that induce inappropriate virus capsid assembly to antiviral effect. To identify attributes of hepatitis B virus (HBV) assembly effectors, assembly reaction products (normal capsid, noncapsid polymer, intermediates, and free dimeric core protein) were quantified in the presence of three experimental effectors: HAP12, HAP13, and AT-130. Effectors bound stoichiometrically to capsid protein polymers, but not free protein. Thermodynamic and kinetic effects, not aberrant assembly, correlate with maximal antiviral activity.

Hepatitis B virus (HBV) is a global public health problem. According to World Health Organization estimates, 360 million people suffer from chronic HBV infection, contributing to approximately 600,000 deaths every year (1). HBV-specific antiviral drug development has focused on targeting the viral reverse transcriptase (RT). However, RT inhibitors do not usually clear HBV infection, even after prolonged treatment (2–4). Furthermore, cessation of RT inhibitors can lead to life-threatening viral flares; therefore, they are generally a lifelong therapy (5). An alternative therapeutic target is highly desirable. One attractive target is assembly of HBV’s capsid from core protein.

HBV is a DNA virus composed of a protein-studded lipid envelope surrounding an icosahedral nucleoprotein core (6, 7). The protein shell of the core, the capsid, is a T = 4 icosahedral complex built from 120 copies of core protein homodimer. The core protein is a 183-amino-acid protein comprised of a 149-residue assembly domain (which includes the dimerization motif) and a C-terminal 34-residue RNA binding domain which is not required for assembly (8). The core protein assembly domain has no human homolog (9). The assembly domain is referred to as Cp149. In the HBV life cycle, like many icosahedral viruses, the capsid has critical roles in virus replication, making it an excellent target for antiviral therapy (10, 11). Cp149 assembly is a function of protein concentration, ionic strength, and temperature (12). A molecule that modulates capsid assembly could interfere with the geometry of core protein interaction, packaging viral nucleic acid, and the stability of newly assembled virions (13–16). A number of HBV assembly effectors have been investigated (17–21). Recently, capsid assembly has also been targeted in other viral systems, including HIV and HCV (22–24).

Two classes of HBV assembly effectors have been discovered in searches for nonnucleoside inhibitors of HBV replication, the heteroaaryldihydropyrimidines (HAPs) and phenylpropenamides (25–29). On the basis of observations with purified Cp149, HAPs increase the kinetics of assembly and strengthen dimer–dimer association to stabilize capsids, and at high concentrations, they misdirect assembly (14, 20). On the basis of a crystal structure of the HAP–HBV complex, a series of HAPs with different properties were designed; their effects on the thermodynamics and kinetics of assembly of purified Cp149 were compared with inhibition of virion production in HepG2.2.15 cells (17, 30). The AT-130 and AT-61 phenylpropenamides had the unusual antiviral activity of generating empty cytoplasmic capsids (31). Like HAPs, phenylpropenamides were shown to accelerate assembly and stabilize capsids; however, they do not misdirect assembly (19). HAPs and AT-130 have antiviral activity in cells, although they have distinct effects on assembly products with purified protein. Because searches for assembly effectors are most efficiently based on biochemical screens, here we identify activities of selected HAPs and phenylpropenamides to define the characteristics that are most important for antiviral activities.

To compare assembly effectors, we have generated phase diagrams of assembly as a function of effector and Cp149 dimer concentrations. To obtain a breadth of understanding of different effectors, we examined HAP12, which substantially strengthens pairwise protein–protein association energy and accelerates kinetics of capsid assembly, and HAP13, which has weaker effects on association energy and kinetics (17). To generalize beyond the HAP family, we included AT-130 in our study (19); structures of these molecules are shown in Fig. 1. To examine equilibrium assembly, Cp149 dimer (at 2.5 to 15 μM in 50 mM HEPES) was incubated with assembly effectors (0 μM to 20 μM) for 20 min.
prior to inducing assembly by addition of NaCl to 150 mM and incubation at 37°C for 24 h. Reaction products were discriminated using 500-Å pore and 1,000-Å pore Agilent BIO SEC 5 size exclusion columns in series (Fig. 2).

The three assembly effectors had distinct effects on capsid assembly. With the strong effector HAP12, the core protein progressively formed large noncapsid polymers, indicated by the decrease in the dimer peak and the shift of the capsid peak toward the void volume (Fig. 2Aa). The continuous shift of the capsid peak was consistent with heterogeneity of assembly products. HAP13, a weak assembly effector, caused intermediates to accumulate without changing the capsid peak, suggesting stabilization of abortive assembly products (Fig. 2Ab). AT-130 induced the formation of more capsid; neither polymer nor intermediate was detected (Fig. 2Ac). Electron micrographs (EM) of the peak center fraction in size exclusion chromatography (SEC) further confirmed the formation of polymers, intermediates, and capsids in the capsid assembly with HAP12, HAP13, and AT-130, respectively.

Because assembly effectors stabilize Cp149-Cp149 interactions, it was likely that they bind tightly to capsid and noncapsid polymers but not necessarily to dimers. Analysis of the UV spectrum of the elution profile was complicated by overlapping absorbance of chromophores and light-scattering artifacts due to large polymers, such as capsid (32). For example, a chromatogram of the assembly of 5 μM Cp149 with 10 μM HAP12 (Fig. 2B) included absorbance of HAP and protein at 280 nm, HAP at 340 nm, and light scattering (which increases at shorter wavelengths) throughout. Analysis of the UV spectra (Fig. 2C) of chromatographic fractions showed that the polymer/capsid had a typical protein peak with an added shoulder from 300 nm to 400 nm corresponding to HAP12, whereas the dimer peak had negligible absorbance in this region. To accurately interpret spectra, we calculated corrections for light scatter and determined the concentrations of Cp149 and assembly effector (32). HAP12 saturated the capsid/polymer complex at a ratio of two HAPs per dimer.
to suppress virion production in culture by 50%, EC50, is represented, or dimer phase when over 50% of the total mass corresponded phases, regions were designated as representing the polymer, cap-
pressed into two dimensions. Since the diagrams have no “pure” phase diagrams show that all three effectors resulted in a dose-
pseudocritical concentration nature of capsid assembly (33). The single “pure” phase exists in the assembly reaction due to the

March 2013 Volume 57 Number 3 aac.asm.org


tivity and also has the greatest kinetic and thermodynamic effects on capsid assembly; its extremely low EC50 would seem to correlate with its kinetic effect (17). Though HAP13 increased the rate of assembly more than AT-130, its effect on dimer-dimer associ-

In conclusion, the antiviral activity of the assembly effectors studied here requires an interplay of the thermodynamics and kinetics induced by the effector. A good assembly effector must be able to initiate capsid assembly fast enough to “escape” the normal capsid assembly path, as well as stabilize intermediates to support further assembly to deplete available core protein.

ACKNOWLEDGMENT

This work was supported by a grant from the National Institutes of Health (R01-AI067417) to A.Z.

REFERENCES


### Table 1: Antiviral activity and thermodynamic and kinetic effects of HAP12, HAP13, and AT-130

<table>
<thead>
<tr>
<th>Assembly effector</th>
<th>EC50 (µM) (mean ± SEM)</th>
<th>ΔG°(m) (kcal/mol) (mean ± SEM)</th>
<th>K_{index} (mean ± SEM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HAP12⁶</td>
<td>0.012 ± 0.002</td>
<td>−1.92 ± 0.07</td>
<td>−3.69 ± 0.05</td>
</tr>
<tr>
<td>AT-130⁶</td>
<td>2.40 ± 0.92</td>
<td>−0.99 ± 0.18</td>
<td>−2.08 ± 0.07</td>
</tr>
<tr>
<td>HAP13⁶</td>
<td>6.10 ± 0.50</td>
<td>−0.69 ± 0.11</td>
<td>−2.41 ± 0.03</td>
</tr>
</tbody>
</table>

⁶ The kinetic index was determined by light scattering experiments as follows: K_{index} = log(slope/concentration of assembly effector), where slope is the steepest slope of the light scattering (LS) trace in arbitrary units, and the assembly effector concentration is micromolar.

Data for HAP12 and HAP13 assembly energetics and EC50 are from reference 17. EC50 was the concentration of the compound required to reduce the concentration of HBV DNA produced in HepG2.2.15 cell culture medium by 50%. DNA concentrations were determined by quantitative Southern blotting.

Data for AT-130 EC50 are from reference 7, where the term 50% inhibitory concentration (IC50) was used to describe results from the same assay as in footnote 6.

Data for AT-130 assembly energetics are from reference 3.


